Journal of Thrombosis and Thrombolysis

, Volume 25, Issue 3, pp 280–283

Prevalence of factor V Leiden (G1691A) and prothrombin (G20210A) among Kurdish population from Western Iran

  • Zohreh Rahimi
  • Asad Vaisi-Raygani
  • Hadi Mozafari
  • Hadi Kharrazi
  • Mansour Rezaei
  • Ronald L. Nagel



The mutation in factor V (FV) G1691A, known as factor V Leiden, and prothrombin (FII) gene G20210A are the two most prevalent causes of inherited thrombophilia. The present study reports the prevalence of factor V Leiden and the prothrombin G20210A gene mutations among healthy individuals of Kurdish ethnic background in Western Iran.


Four hundred thirty-four healthy unrelated individuals, 255 male and 179 female, with a mean age of 28.7 ± 15.5 from the Kermanshah Province of Iran were studied for prothrombin G20210A mutation. The factor V Leiden mutation was studied in 404 healthy individuals, of whom 232 were male and 172 were female. The factor V Leiden and prothrombin G20210A were detected by polymerase chain reaction–restriction fragment-length polymorphism (PCR-RFLP) method using Mnl I and Hind III restriction enzymes, respectively.


Among 434 individuals studied for prothrombin G20210A mutation seven carried this mutation as heterozygous (four female subjects and three male), giving a prevalence of 1.6% [95% confidence intervals (CI) 0.5–2.7) and an allele frequency of 0.8%. No homozygous prothrombin 20210AA was found. Factor V G1691A mutation was detected as heterozygous in 11 of 404 healthy individuals (five female and six male) and as homozygous in one male indicating a prevalence of 2.97% (95% CI 1.3–4.6) and allele frequency of 1.6%.


Our results indicated that the factor V Leiden and prothrombin G20210A mutations are not rare among populations of Western Iran and that the relationship between venous thrombophilia and these mutations have to be further studied in Western Iran population, which, in turn, may suggest a causal effect.


Factor V Leiden Prevalence Prothrombin G20210A Western Iran 


  1. 1.
    Endler G, Mannhalter C (2003) Polymorphisms in coagulation factor genes and their impact on arterial and venous thrombosis. Clin Chim Acta 330:31–55PubMedCrossRefGoogle Scholar
  2. 2.
    Poort SR, Rosendaal FR, Reitsma PH, Bertina RM (1996) A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88:3698–3703PubMedGoogle Scholar
  3. 3.
    Ridker PM, Golhaber SZ, Danielson E et al (2003) Long warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 348:1425–1434PubMedCrossRefGoogle Scholar
  4. 4.
    Kearon C, Ginsberg JS, Kovacs MJ et al (2003) Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-therm prevention of recurrent venous thromboembolism. N Engl J Med 349:631–639PubMedCrossRefGoogle Scholar
  5. 5.
    Said JM, Brennecke SP, Moses EK et al (2006) Ethnic differences in the prevalence of inherited thrombophilic polymorphisms in an asymptomatic Australian prenatal population. Hum Biol 78:403–412PubMedCrossRefGoogle Scholar
  6. 6.
    Awidi A, Shannak M, Bseiso A et al (1999) High prevalence of factor V Leiden in healthy Jordanian Arabs. Thromb Haemost 81:582–584PubMedGoogle Scholar
  7. 7.
    Irani-Hakime N, Tamim H, Kreidy R, Almawi WY (2000) The prevalence of factor V R506Q mutation Leiden among apparently healthy Lebanese. Am J Hematol 65:45–49PubMedCrossRefGoogle Scholar
  8. 8.
    Angchaisuksiri P, Pingsuthiwong S et al (2000) Prevalence of the G1691A mutation in the factor V gene (factor V Leiden) and the G20210A prothrombin gene mutation in the Thai population. Am J Hematol 65:119–122PubMedCrossRefGoogle Scholar
  9. 9.
    Rees DC, Cox M, Clegg JB (1995) World distribution of factor V Leiden. Lancet 346:1133–1134PubMedCrossRefGoogle Scholar
  10. 10.
    Zeinali S, Duca F, Zarbakhsh B, Tagliabue L, Mannucci PM (2000) Thrombophilic mutations in Iran. Thromb Haemost 83:351–352PubMedGoogle Scholar
  11. 11.
    Old JM, Higgs DR (1983) Gene analysis. In: Weatherall DJ (ed) Methods in hemotology. The thalassemias, vol 6. Churchill Livingstone, London, pp 74–101Google Scholar
  12. 12.
    Bertina RM, Koeleman BPC, Koster T et al (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369:64–67PubMedCrossRefGoogle Scholar
  13. 13.
    Zivelin A, Griffin JH, Xu X et al (1997) A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood 89:397–402PubMedGoogle Scholar
  14. 14.
    Lucotte G, Mercier G (2001) Population genetics of factor V Leiden in Europe. Blood Cells Mol Dis 27:362–367PubMedCrossRefGoogle Scholar
  15. 15.
    Almawi WY, Keleshian SH, Borgi L et al (2005) Varied prevalence of factor V G1691A (Leiden) and prothrombin G20210A single nucleotide polymorphisms among Arabs. J Thromb Thrombolysis 20:163–168PubMedCrossRefGoogle Scholar
  16. 16.
    Garewal G, Das R, Trehan U (1997) Factor V Leiden: prevalence in the indigenous population and cases of thrombosis in north India. Br J Haematol 97:940PubMedGoogle Scholar
  17. 17.
    Abu-Amero KK, Wyngaard CA, Kambouris M, Dzimiri N (2002) Prevalence of the 20210G→A prothrombin variant and its association with coronary artery disease in a Middle Eastern Arab population. Arch Pathol Lab Med 126:1087–1090PubMedGoogle Scholar
  18. 18.
    Akar N, Misirlioglu M, Akar E, Avcu F, Yalcin A, Sozuoz A (1998) Prothrombin gene 20210G-A mutation in the Turkish population. Am J Hematol 58:249PubMedCrossRefGoogle Scholar
  19. 19.
    Rosendaal FR, Doggen CJ, Zivelin A et al (1998) Geographic distribution of the 20210G to A prothrombin variant. Thromb Haemost 79:706–708PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Zohreh Rahimi
    • 1
    • 2
  • Asad Vaisi-Raygani
    • 2
  • Hadi Mozafari
    • 1
  • Hadi Kharrazi
    • 2
  • Mansour Rezaei
    • 3
  • Ronald L. Nagel
    • 4
    • 5
  1. 1.Medical Biology Research CentreKermanshah University of Medical SciencesKermanshahIran
  2. 2.Department of Biochemistry, Medical SchoolKermanshah University of Medical SciencesKermanshahIran
  3. 3.Department of Biostatistics, Medical SchoolKermanshah University of Medical SciencesKermanshahIran
  4. 4.Department of Medicine, Division of HematologyAlbert Einstein College of MedicineBronxUSA
  5. 5.Department of Physiology and BiophysicsAlbert Einstein College of MedicineBronxUSA

Personalised recommendations